Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Treasury Shares (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Treasury Shares for 6 consecutive years, with $802.5 million as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares changed 0.0% year-over-year to $802.5 million; the TTM value through Mar 2026 reached $802.5 million, changed 0.0%, while the annual FY2025 figure was $802.5 million, 0.0% changed from the prior year.
  • Treasury Shares hit $16.2 million in Q1 2026 for Agios Pharmaceuticals, roughly flat from $16.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $16.2 billion in Q1 2022 and bottomed at $16.2 million in Q4 2022.
  • Average Treasury Shares over 5 years is $10.5 billion, with a median of $16.2 billion recorded in 2022.
  • On a YoY basis, Treasury Shares climbed as much as 51.69% in 2022 and fell as far as 0.0% in 2022.
  • Agios Pharmaceuticals' Treasury Shares stood at $802.5 million in 2022, then changed by 0.0% to $802.5 million in 2023, then changed by 0.0% to $802.5 million in 2024, then changed by 0.0% to $802.5 million in 2025, then changed by 0.0% to $802.5 million in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $802.5 million, $802.5 million, and $802.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.